Applied dna and evvivax announce peer-reviewed publication of positive preclinical data for lineardna™ platform as a novel cancer vaccine strategy in the journal of experimental & clinical cancer research

Stony brook, n.y. and rome, italy--(business wire)---- $apdn #lineardna--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in cell-free, enzymatic dna production, and its program development partner, evvivax, s.r.l. ("evvivax"), today announced the peer-reviewed publication of preclinical animal data in the journal of experimental & clinical cancer research that supports the use of applied dna's lineardna™ platform to produce veterinary dna cancer vaccines. lineardna is applied dna's proprieta
APDN Ratings Summary
APDN Quant Ranking